Angiopoietin-2 blocking antibodies reduce early atherosclerotic plaque development in mice

Atherosclerosis

Volumn 241, Issue 2, 2015, Pages 297-304

  Theelen, Thomas L ^a   Lappalainen, Jari P ^b   Sluimer, Judith C ^a   Gurzeler, Erika ^b   Cleutjens, Jack P ^a   Gijbels, Marion J ^a,c   Biessen, Erik A L ^a   Daemen, Mat J A P ^c   Alitalo, Kari ^d   Ylä Herttuala, Seppo ^b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Angiogenesis; Angiopoietin 2; Atherosclerosis; Microvascular leakage; Plaque stability

Indexed keywords

ANGIOPOIETIN 2; ANGIOPOIETIN 2 BLOCKING ANTIBODY; BLOCKING ANTIBODY; CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ANTIBODY; APOLIPOPROTEIN B100; CHOLESTEROL INTAKE; LOW DENSITY LIPOPROTEIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ROOT; ARTERY DIAMETER; ARTICLE; BRACHIOCEPHALIC TRUNK; CAROTID ARTERY; CAROTID ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; ANTAGONISTS AND INHIBITORS; AORTA; AORTIC DISEASES; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD; CAROTID ARTERY DISEASES; CHOLESTEROL INTAKE; COMPLICATION; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; GENETICS; HYPERCHOLESTEROLEMIA; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; TIME FACTOR;

ANGIOPOIETIN-2; ANIMALS; ANTIBODIES; AORTA; AORTIC DISEASES; APOLIPOPROTEIN B-100; ATHEROSCLEROSIS; BRACHIOCEPHALIC TRUNK; CAROTID ARTERIES; CAROTID ARTERY DISEASES; CHOLESTEROL, DIETARY; DISEASE MODELS, ANIMAL; HYPERCHOLESTEROLEMIA; MALE; MICE, KNOCKOUT; PLAQUE, ATHEROSCLEROTIC; RECEPTORS, LDL; TIME FACTORS; TRIGLYCERIDES;

EID: 84936064097     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.05.018     Document Type: Article

References (50)

1. Llovet J.M., et al. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin. Cancer Res. 2012, 18:2290-2300.
2. Ziegler T., et al. Angiopoietin 2 mediates microvascular and hemodynamic alterations in sepsis. J.Clin. Invest. 2013, 123(8):3436-3445.
3. Iribarren C., et al. Circulating angiopoietins-1 and -2, angiopoietin receptor tie-2 and vascular endothelial growth factor-a as biomarkers of acute myocardial infarction: a prospective nested case-control study. BMC Cardiovasc. Disord. 2011, 11:31.
4. Le Dall J., et al. Immaturity of microvessels in haemorrhagic plaques is associated with proteolytic degradation of angiogenic factors. Cardiovasc. Res. 2010, 85:184-193.
5. Post S., et al. Balance between angiopoietin-1 and angiopoietin-2 is in favor of angiopoietin-2 in atherosclerotic plaques with high microvessel density. J.Vasc. Res. 2008, 45:244-250.
6. Ahmed A., et al. Angiopoietin-2 confers atheroprotection in apoe-/- mice by inhibiting ldl oxidation via nitric oxide. Circ. Res. 2009, 104:1333-1336.
7. Bowles E.J., et al. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J.Natl. Cancer Inst. 2012, 104:1293-1305.
8. Chen J., et al. Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J.Am. Coll. Cardiol. 2012, 60:2504-2512.
9. Choueiri T.K., et al. Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J.Clin. Oncol. 2011, 29:632-638.
10. Scappaticci F.A., et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J.Natl. Cancer Inst. 2007, 99:1232-1239.
11. Saharinen P., et al. Vegf and angiopoietin signaling in tumor angiogenesis and metastasis. Trends Mol. Med. 2011, 17:347-362.
12. Leow C.C., et al. Medi3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models. Int. J. Oncol. 2012, 40:1321-1330.
13. Fiedler U., et al. Angiopoietin-2 sensitizes endothelial cells to tnf-alpha and has a crucial role in the induction of inflammation. Nat. Med. 2006, 12:235-239.
14. Lobov I.B., et al. Angiopoietin-2 displays vegf-dependent modulation of capillary structure and endothelial cell survival invivo. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:11205-11210.
15. Benest A.V., et al. Angiopoietin-2 is critical for cytokine-induced vascular leakage. PLoS One 2013, 8:e70459.
16. Bhandari V., et al. Hyperoxia causes angiopoietin 2-mediated acute lung injury and necrotic cell death. Nat. Med. 2006, 12:1286-1293.
17. Murdoch C., et al. Expression of tie-2 by human monocytes and their responses to angiopoietin-2. J.Immunol. 2007, 178:7405-7411.
18. Yla-Herttuala S., et al. Stabilization of atherosclerotic plaques: an update. Eur. Heart J. 2013, 34:3251-3258.
19. Moreno P.R., et al. Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: implications for plaque vulnerability. Circulation 2004, 110:2032-2038.
20. Sluimer J.C., et al. Thin-walled microvessels in human coronary atherosclerotic plaques show incomplete endothelial junctions relevance of compromised structural integrity for intraplaque microvascular leakage. J.Am. Coll. Cardiol. 2009, 53:1517-1527.
21. von der Thusen J.H., et al. Induction of rapid atherogenesis by perivascular carotid collar placement in apolipoprotein e-deficient and low-density lipoprotein receptor-deficient mice. Circulation 2001, 103:1164-1170.
22. Holopainen T., et al. Effects of angiopoietin-2-blocking antibody on endothelial cell-cell junctions and lung metastasis. J.Natl. Cancer Inst. 2012, 104:461-475.
23. Huusko J., et al. Aav9-mediated vegf-b gene transfer improves systolic function in progressive left ventricular hypertrophy. Mol. Ther. 2012, 20:2212-2221.
24. Feintuch A., et al. Hemodynamics in the mouse aortic arch as assessed by mri, ultrasound, and numerical modeling. Am. J. Physiol. Heart Circ. Physiol. 2007, 292:H884-H892.
25. Castier Y., et al. P47phox-dependent nadph oxidase regulates flow-induced vascular remodeling. Circ. Res. 2005, 97:533-540.
26. Lutgens E., et al. Atherosclerosis in apoe*3-leiden transgenic mice: from proliferative to atheromatous stage. Circulation 1999, 99:276-283.
27. Natale R.B., et al. Safety, pharmacokinetics, and antitumor activity of medi3617, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J.Clin. Oncol. 2012, 30. (suppl; abstr TPS2621).
28. Lutgens E., et al. Requirement for cd154 in the progression of atherosclerosis. Nat. Med. 1999, 5:1313-1316.
29. Johansen C.T., et al. Using mendelian randomization to determine causative factors in cardiovascular disease. J.Intern Med. 2013, 273:44-47.
30. Jorgensen A.B., et al. Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. Eur. Heart J. 2013, 34:1826-1833.
31. Watts G.F., et al. Demystifying the management of hypertriglyceridaemia. Nat. Rev. Cardiol. 2013, 10:648-661.
32. Goldstein J.L., et al. Cholesteryl ester accumulation in macrophages resulting from receptor-mediated uptake and degradation of hypercholesterolemic canine beta-very low density lipoproteins. J.Biol. Chem. 1980, 255:1839-1848.
33. Wang L., et al. Triglyceride-rich lipoprotein lipolysis releases neutral and oxidized ffas that induce endothelial cell inflammation. J.Lipid Res. 2009, 50:204-213.
34. Triglyceride Coronary Disease Genetics C, et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 2010, 375:1634-1639.
35. Scholz A., et al. Angiopoietin-2 promotes myeloid cell infiltration in a beta(2)-integrin-dependent manner. Blood 2011, 118:5050-5059.
36. Hakanpaa L., et al. Endothelial destabilization by angiopoietin-2 via integrin beta1 activation. Nat. Commun. 2015, 6:5962.
37. Syrjala S.O., et al. Angiopoietin-2 inhibition prevents transplant ischemia-reperfusion injury and chronic rejection in rat cardiac allografts. Am. J. Transpl. 2014, 14:1096-1108.
38. Nykanen A.I., et al. Angiopoietin-1 protects against the development of cardiac allograft arteriosclerosis. Circulation 2003, 107:1308-1314.
39. Augustin H.G., et al. Control of vascular morphogenesis and homeostasis through the angiopoietin-tie system. Nat. Rev. Mol. Cell Biol. 2009, 10:165-177.
40. Kienast Y., et al. Ang-2-vegf-a crossmab, a novel bispecific human igg1 antibody blocking vegf-a and ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy. Clin. Cancer Res. 2013, 19:6730-6740.
41. Chung N.A., et al. Measurement of the soluble angiopoietin receptor tie-2 in patients with coronary artery disease: development and application of an immunoassay. Eur. J. Clin. Invest. 2003, 33:529-535.
42. David S., et al. Angiopoietin 2 and cardiovascular disease in dialysis and kidney transplantation. Am. J. Kidney Dis. 2009, 53:770-778.
43. David S., et al. Circulating angiopoietin-2 in essential hypertension: relation to atherosclerosis, vascular inflammation, and treatment with olmesartan/pravastatin. J.Hypertens. 2009, 27:1641-1647.
44. Golledge J., et al. Increased serum angiopoietin-2 is associated with abdominal aortic aneurysm prevalence and cardiovascular mortality in older men. Int. J. Cardiol. 2013, 167:1159-1163.
45. Lee K.W., et al. Plasma angiopoietin-1, angiopoietin-2, angiopoietin receptor tie-2, and vascular endothelial growth factor levels in acute coronary syndromes. Circulation 2004, 110:2355-2360.
46. Patel J.V., et al. Angiopoietin-2 levels as a biomarker of cardiovascular risk in patients with hypertension. Ann. Med. 2008, 40:215-222.
47. Wang X., et al. Changes and significance of serum angiopoietin-2 levels in patients with coronary heart disease. Biomarkers 2012, 17:745-749.
48. Calvi C., et al. Angiopoietin 2 induces cell cycle arrest in endothelial cells: a possible mechanism involved in advanced plaque neovascularization. Arterioscler. Thromb. Vasc. Biol. 2004, 24:511-518.
49. Chen F., et al. Apoptosis and angiogenesis are induced in the unstable coronary atherosclerotic plaque. Coron. Artery Dis. 2005, 16:191-197.
50. Pelisek J., et al. Neovascularization and angiogenic factors in advanced human carotid artery stenosis. Circ. J. 2012, 76:1274-1282.